Citations

Showing 10 of 108094 citations.

Tumor-infiltrating lymphocytes in androgen receptor-positive, triple-negative breast cancer.
Leon‐Ferre, Roberto A. , Polley, Mei‐Yin C. , Liu, Heshan , Cafourek, Victoria, Negron, Vivian , Liu, Minetta C. , Visscher, Daniel W., Boughey, Judy C. , Kalari, Krishna R. , Ingle, James N. , Couch, Fergus J. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 5_suppl | Pages: 5-5

10.1200/jco.2018.36.5_suppl.5 Get It

5 Background: Triple-negative breast cancer (TNBC) is an immunogenic breast cancer subtype, with a greater percentage of tumors containing tumor-infiltrating lymphocytes (TILs) compared to non-TNBC. TILs are prognostic for recurrence and predictive for chemotherapy benefit in TNBC, but not in estrogen receptor (ER)-positive tumors. A subset of TNBC expresses the androgen receptor (AR), and resembles ER-positive breast cancer in terms of demographics (older age) and clinical course (later recurrences that tend to involve bone). However, little is known regarding the association between TILs and AR expression in TNBC. Methods: From a cohort of 9982 women with surgically-treated non-metastatic breast cancer, patients who met criteria for TNBC (ER/PR < 1% and HER2-negative) by centralized-pathology review were included as previously published [Leon-Ferre et al, Breast Cancer Res Treat 2017]. Stromal TILs in these tumors were quantified on full-face hematoxylin and eosin sections from the surgical specimen, following the 2014 TIL Working Group recommendations [Salgado et al, Ann Oncol 2014]. The expression of AR [EPR1535(2), Abcam] was scored as a continuous variable (1% increments), and categorized as absent (0%), low (1-25% ), low-moderate (26-50%) moderate (51-75%) and high (> 75%) and correlated with TIL density. Results: 605 patients met criteria for TNBC. The median age was 56 years. Most tumors were T1-2 (95%), N0-1 (86%), and high grade (88%). The median stromal TIL content was 20% (0-90%). Tumor tissue was available for AR staining in 509/605 patients. 165 (32%) tumors expressed AR as follows: low: 12%, low-moderate: 7%, moderate: 5%, and high: 8%. Apocrine tumors (n = 30) expressed AR most frequently (86%) and at higher levels (AR high: 50%). For all 509 tumors, the median stromal TIL content according to AR expression was AR absent: 20%, AR low: 20%, AR low-moderate: 15%, AR high: 10%. AR and stromal TILs (both as continuous variables) demonstrated a weak inverse correlation (correlation coefficient -0.1064, p = 0.017). Conclusions: AR expression in TNBC is associated with lower levels of stromal TILs. Additional data correlating the AR, stromal TILs and outcomes in this cohort will be presented at the meeting.
T cell responses to tumor associated antigens in multiple myeloma patients treated with MV-NIS, an oncolytic measles virus.
Upreti, Deepak , Zhou, Yumei , Peng, Kah Whye, Packiriswamy, Nandakumar , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 5_suppl | Pages: 218-218

10.1200/jco.2018.36.5_suppl.218 Get It

218 Background: Evidence from mouse studies shows that Oncolytic viral mode of tumor cell killing can boost the cytotoxic T lymphocyte response against tumor associated antigens (TAA), leading to ‘bystander’ killing of uninfected tumor cells. Methods: To investigate whether oncolytic virotherapy can boost immune responses to tumor antigens in human subjects we studied T cell responses to 10 different TAA reported to have high expression in patients with multiple myeloma (n = 10) before and after intravenous administration of an oncolytic measles virus (MV-NIS). Baseline and 6 week post-therapy PBMC samples were stimulated with peptides specific to each of the selected TAA and their responses to this antigenic stimulation were measured using IFNγ ELISPOT. Results: Despite their prior exposure to multiple immunosuppressive treatment regimens, some of the tested patients had higher T cell responses to some of the TAA even prior to MV-NIS. Baseline T cell responses against MAGEc1 were present in 50% of the patients, and against hTERT and NYESO-1 in 30% of the patients. Furthermore, MV-NIS treatment significantly boosted T cell responses against NYESO-1, MAGEc1, MAGEA1 and MUC1 in 40% of the patients. Interestingly, in one outlier patient who achieved a stringent and durable complete disease remission after MV-NIS therapy, strong baseline T cell responses were present against 8 of the 10 tested TAA but did not change significantly after virotherapy. Based on the T cell responses to the TAA, three distinct phenotypes can be identified. Phenotype 1 was characterized by positive T cell responses to TAA prior and post therapy, Phenotype 2 was characterized by positive T cell responses to TAA only post therapy and phenotype 3 was characterized by negative T cell responses to TAA prior and post therapy. Conclusions: Our data suggests oncolytic measles virotherapy boosted the cytotoxic T lymphocyte response against tumor associated antigens in some of the patients. Identifying patient’s phenotype based on responsiveness to the TAA could be useful marker for identifying the immune responsive state in multiple myeloma patients and identify patients who can be most responsive to oncolytic measles virotherapy. Clinical trial information: NCT00450814.
A clinical insight into therapeutic sequence in advanced melanoma.
Aguilera, Jesus Vera, Tschautscher, Marcella , Yu, Cecilia, Duma, Narjust , Markovic, Svetomir, Paludo, Jonas , Markovic, Svetomir N.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 5_suppl | Pages: 186-186

10.1200/jco.2018.36.5_suppl.186 Get It

186 Background: The optimal sequence strategy of BRAF/MEK inhibitors, anti-PD- 1/PDL-1 and anti-CTLA-4 in metastatic BRAF-mutated melanoma patients (pts) is unknown and no treatment guidelines exist. Therefore, we report a single-institution experience of different treatment approaches using targeted therapy (TT) and immunotherapy and its impact on outcomes. Methods: BRAF-mutated metastatic melanoma pts treated with TT and immunotherapy from 2012 to2017 were analyzed. Six groups were identified based on treatment strategy. All time-to-event analyses were calculated using the Kaplan-Meier method and Wilcoxon test. Results: Forty-four pts were identified. The median age at diagnosis was 49 years (range 21-73), 54% pts were females and 43% developed brain metastases during disease course. The most common approach strategy was immunotherapy followed by TT, the median duration of treatment was 11 and 19 weeks, respectively. Time-to-next therapy (TTNT) following 1st line treatment was similar in pts treated with TT (median 23 weeks [95% CI: 15-31]) or immunotherapy (median 26 weeks [95% CI: 10-33], p = 0.94). A trend towards better overall survival (OS) was seen in pts who received immunotherapy followed by TT (p = 0.09); patients who received salvage chemotherapy (carboplatin/paclitaxel) had significantly longer OS (median 7 years [95% CI: 3.2-7.08]) ( p = 0.03). Conclusions: No differences in TTNT were seen with immunotherapy, TT or combined (triple therapy) when used as 1st or 2nd line. The significant longer OS benefit with 1st line immunotherapy was only seen in patients who received chemotherapy later in their treatment course. [Table: see text]
High-dimensional regression analysis links magnetic resonance imaging features and protein expression and signaling pathway alterations in breast invasive carcinoma
Lehrer, Michael, Aithala, Sathvik Panambur, Ravikumar, Visweswaran , Zheng, Youyun , Bonaccio, Emerlinda, Net, Jose , Brandt, Kathy R., Ganott, Marie A., Zuley, Margarita L. , Rao, Arvind , Brandt, Kathy, Bhadra, Anindya , Dogan, Basak E , Burnside, Elizabeth S. , Morris, Elizabeth A. , Sutton, Elizabeth J. , Whitman, Gary J.

Mayo Clinic

Oncoscience | February 26, 2018 | Volume: 5 | Issue: 1-2 | Pages: 39-48

10.18632/oncoscience.397 | PMID 29556516 Get It

Quality assurance tool for organ at risk delineation in radiation therapy using a parametric statistical approach
Hui, C , Nourzadeh, Hamidreza , Watkins, William T., Alonso, Clayton E., Dutta, Sunil W. , Siebers, Jeffrey V. , Trifiletti, Daniel M.

Mayo Clinic

Medical Physics | February 26, 2018 | Volume: 45 | Issue: 5 | Pages: 2089-2096

10.1002/mp.12835 | PMID 29481703 Get It

PurposeTo develop a quality assurance (QA) tool that identifies inaccurate organ at risk (OAR) delineations.MethodsThe QA tool computed volumetric features from prior OAR delineation data from 73 thoracic patients to construct a reference database. All volumetric features of the OAR delineation are computed in three‐dimensional space. Volumetric features of a new OAR are compared with respect to those in the reference database to discern delineation outliers. A multicriteria outlier detection system warns users of specific delineation outliers based on combinations of deviant features. Fifteen independent experimental sets including automatic, propagated, and clinically approved manual delineation sets were used for verification. The verification OARs included manipulations to mimic common errors. Three experts reviewed the experimental sets to identify and classify errors, first without; and then 1 week after with the QA tool.ResultsIn the cohort of manual delineations with manual manipulations, the QA tool detected 94% of the mimicked errors. Overall, it detected 37% of the minor and 85% of the major errors. The QA tool improved reviewer error detection sensitivity from 61% to 68% for minor errors (P = 0.17), and from 78% to 87% for major errors (P = 0.02).ConclusionsThe QA tool assists users to detect potential delineation errors. QA tool integration into clinical procedures may reduce the frequency of inaccurate OAR delineation, and potentially improve safety and quality of radiation treatment planning.
A clinically relevant IMRT QA workflow: Design and validation
Stambaugh, Cassandra , Ezzell, Gary A., Ezzell, Gary

Mayo Clinic

Medical Physics | February 26, 2018 | Volume: 45 | Issue: 4 | Pages: 1391-1399

10.1002/mp.12838 | PMID 29481698 Get It

PurposeThe purpose of this study was to determine clinically relevant pass/question/fail criteria for gamma analysis of intensity‐modulated radiation therapy quality assurance (IMRT QA) plans, identify which plans should be further analyzed with dose–volume histogram (DVH) metrics, and create a workflow for performing that DVH‐based analysis.MethodsA total of 11 plans, 5 prostate and 6 head/neck, were selected to represent known good plans based on their high‐passing rate using conventional IMRT QA criteria. These were modified by moving the programmed MLC positions to underdose the target or overdose important structures by varying amounts. Commercially available hardware/software was used to measure and analyze all plans (76 total) using 4%/3 mm, 3%/3 mm, 3%/2 mm, and 2%/2 mm gamma criteria. Two receiver operator characteristic (ROC) curves per criterion were created to assess effective passing rates. One ROC curve was to find a higher threshold that determined a clear pass and the second to find a lower threshold to determine a clear failure. Plans between these two thresholds need DVH‐based analysis to assess the clinical consequence of the dose difference. The modified plans were analyzed in the planning system and reconstructed in commercially available DVH‐based analysis software to access the accuracy and usefulness of the software.ResultsAnalysis of the ROC curves showed optimal pass and fail thresholds for plan error detection per criterion to achieve clinically relevant sensitivity and specificity. Based on measurement uncertainty and pass/fail ranges, 3%/2 mm gamma criteria with a pass threshold of 95% and a fail threshold of 90% were most optimal. DVH analysis showed good agreement with all reconstructed plans except where the changes to the MLC patterns caused the periphery of the target to be underdosed. For questionable plans, comparing the organ‐specific DVHs to the physician‐provided planning constraints proved to be an efficient and effective workflow since plans for which the target dose was slightly high or where organs at risk were underdosed could be released for the treatment without consulting the physician for a clinical decision.ConclusionThis work indicates the potential for appreciable improvement in error detection for IMRT QA. Using effective pass/fail thresholds to determine plans that need DVH‐based analysis minimizes the need for excessive, time‐consuming, analysis, and making use of the dosimetric constraints of the plan minimizes the burden on physicians. Overall, DVH‐based analysis is a powerful tool that can provide substantial insight over the traditional approach that does not provide structure‐specific data.
Sheehan’s Syndrome Revisited: Underlying Autoimmunity or Hypoperfusion?
González‐González, José Gerardo , Borjas‐Almaguer, Omar D. , Salcido‐Montenegro, Alejandro , Rodríguez-Guajardo, René, Elizondo-Plazas, Anasofía , Montes‐de‐Oca‐Luna, Roberto , Rodríguez‐Gutiérrez, René , González-González, José Gerardo

Mayo Clinic

International Journal of Endocrinology | February 26, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-8

10.1155/2018/8415860 | PMID 29681937 Get It

Sheehan’s syndrome remains a frequent obstetric complication with an uncertain pathophysiology. We aimed to assess the incidence of hypopituitarism (≥2 hormonal axis impairment) within the first six postchildbirth months and to determine the existence of anti-pituitary antibodies. From 2015 to 2017, adult pregnant women, who developed moderate to severe postpartum hemorrhage (PPH), were consecutively included in the study. Pituitary function was assessed 4 and 24 weeks after PPH. At the end of the study, anti-pituitary antibodies were assessed. Twenty women completed the study. Mean age was 26.35 (±5.83) years. The main etiology for severe PPH was uterine atony (65%) which resulted mostly in hypovolemic shock grades III-IV. Within the first four weeks after delivery, 95% of patients had at least one hormonal pituitary affected and 60% of the patients fulfilled diagnostic criteria for hypopituitarism. At the end of the study period, five patients (25%) were diagnosed with hypopituitarism (GH and cortisol axes affected). Anti-pituitary antibodies were negative in all patients. At 6 months follow-up, one in every four women with a history of moderate-to-severe PPH was found with asymptomatic nonautoimmune-mediated hypopituitarism. The role of autoimmunity in Sheehan’s syndrome remains uncertain. Further studies are needed to improve the remaining knowledge gaps.
Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device
Thompson, Jocelyn S. , LaRue, Shane , Lewis, Eldrin F. , Patel, Chetan B. , Blue, Laura , Fairclough, Diane L., Leister, Erin, Cleveland, Joseph C. , Phillips, Clifford , Baldridge, Vicie, Walsh, Mary Norine , Matlock, Daniel D. , Dunlay, Shannon M. , Matlock, Daniel D , Allen, Larry A. , McIlvennan, Colleen Kelley , Glasgow, Russell E.

Mayo Clinic

JAMA Internal Medicine | February 26, 2018 | Volume: 178 | Issue: 4 | Pages: 520

10.1001/jamainternmed.2017.8713 | PMID 29482225 Get It

Atherosclerotic vascular disease in the autoimmune rheumatologic woman
Kurmann, Reto , Mankad, Rekha , Kurmann, Reto Daniel, Mankad, Rekha

Mayo Clinic

Clinical Cardiology | February 26, 2018 | Volume: 41 | Issue: 2 | Pages: 258-263

10.1002/clc.22916 | PMID 29480591 Get It

Autoimmune rheumatologic conditions have increased cardiovascular morbidity and mortality compared to the general population. Many of these diseases occur more commonly in women, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and Sjogren's. Most of the literature that has identified the link between autoimmune diseases and atherosclerotic cardiovascular disease (ASCVD) has been regarding patients with RA and SLE. The reason for the increased ASCVD is related to both traditional risk factors for atherosclerosis and nontraditional risk factors such as the burden of inflammation. Presently, our ability to adequately determinecardiovascular risk in the autoimmune patient is subpar, as scoring systems fail to take into account the role of inflammation. No present guidelines exist that take into account the increased burden of cardiovascular disease in this complex patient cohort.
A Soft Microenvironment Protects from Failure of Midbody Abscission and Multinucleation Downstream of the EMT-Promoting Transcription Factor Snail
Simi, Allison K., Anlaş, Alişya A. , Stallings‐Mann, Melody , Zhang, Sherry, Hsia, Tiffaney , Cichon, Magdalena A., Nelson, Celeste M. , Cichon, Magdalena, Radisky, Derek C.

Mayo Clinic

Cancer Research | February 26, 2018 | Volume: 78 | Issue: 9 | Pages: 2277-2289

10.1158/0008-5472.can-17-2899 | PMID 29483094 Get It

Abstract Multinucleation is found in more than one third of tumors and is linked to increased tolerance for mutation, resistance to chemotherapy, and invasive potential. The integrity of the genome depends on proper execution of the cell cycle, which can be altered through mechanotransduction pathways as the tumor microenvironment stiffens during tumorigenesis. Here, we show that signaling downstream of matrix metalloproteinase-3 (MMP3) or TGFβ, known inducers of epithelial–mesenchymal transition (EMT), also promotes multinucleation in stiff microenvironments through Snail-dependent expression of the filament-forming protein septin-6, resulting in midbody persistence, abscission failure, and multinucleation. Consistently, we observed elevated expression of Snail and septin-6 as well as multinucleation in a human patient sample of metaplastic carcinoma of the breast, a rare classification characterized by deposition of collagen fibers and active EMT. In contrast, a soft microenvironment protected mammary epithelial cells from becoming multinucleated by preventing Snail-induced upregulation of septin-6. Our data suggest that tissue stiffening during tumorigenesis synergizes with oncogenic signaling to promote genomic abnormalities that drive cancer progression. Significance: These findings reveal tissue stiffening during tumorigenesis synergizes with oncogenic signaling to promote genomic abnormalities that drive cancer progression. Cancer Res; 78(9); 2277–89. ©2018 AACR.